Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients

References

• WHO | Mental health action plan 2013-2020. WHO [Internet]. World Health Organization; 2015 [cited October 16, 2020]. Available from: http://www.who.int/entity/mental_health/publications/action_plan/en/index.html. Accessed July 28, 2021.
   Google Scholar
• McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67–76. doi:10.1093/epirev/mxn001
   PubMed Web of Science ®Google Scholar
• NIMH. Schizophrenia [Internet]. [cited March 7, 2021]. Available from: https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml. Accessed July 28, 2021.
   Google Scholar
• Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114(1):169–179. doi:10.1093/bmb/ldv017
   PubMed Web of Science ®Google Scholar
• Ozomaro U, Wahlestedt C, Nemeroff CB. Personalized medicine in psychiatry: problems and promises. BMC Med. 2013;11(1):1–35. doi:10.1186/1741-7015-11-132
   Web of Science ®Google Scholar
• Jin H, Mosweu I. The societal cost of schizophrenia: a systematic review. Pharmacoeconomics. 2017;35:25–42. doi10.1007/s40273-016-0444-6
   PubMed Web of Science ®Google Scholar
• Unim B, Pitini E, De Vito C, D’Andrea E, Marzuillo C, Villari P.Cost-effectiveness of RAS genetic testing strategies in patients with metastatic colorectal cancer: a systematic review. Value Health. 2020;23:114–126. doi:10.1016/j.jval.2019.07.009
   Web of Science ®Google Scholar
• Martín AS, Gómez AI, García-Berrocal B, et al. Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. Pharmacogenomics. 2014;15:997–1006. doi:10.2217/pgs.14.48
   PubMed Web of Science ®Google Scholar
• Borse MS, Dong OM, Polasek MJ, Farley JF, Stouffer GA, Lee CR. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. Pharmacogenomics. 2017;18(12):1155–1166. doi:10.2217/pgs-2017-0075
   Web of Science ®Google Scholar
• Zhu Y, Swanson KM, Rojas RL, et al. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. Genet Med. 2020;22:475–486.
   PubMed Web of Science ®Google Scholar
• Pink J, Pirmohamed M, Lane S, Hughes DA. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. Alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther. 2014;95(2):199–207. doi:10.1038/clpt.2013.190
   PubMed Web of Science ®Google Scholar
• Berm EJJ, Hak E, Postma M, et al. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial). Trials. 2015;16(1):1–8. doi:10.1186/s13063-015-0561-0
   Web of Science ®Google Scholar
• Verhoef TI, Redekop WK, Van Schie RM, et al. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics. 2012;13:1405–1417. doi:10.2217/pgs.12.124
   PubMed Web of Science ®Google Scholar
• Sluiter RL, Kievit W, Van Der Wilt GJ, et al. Cost-effectiveness analysis of genotype-guided treatment allocation in patients with alcohol use disorders using naltrexone or acamprosate, using a modeling approach. Eur Addict Res. 2018;24(5):245–254. doi:10.1159/000494127
   Web of Science ®Google Scholar
• De Monaco A, Berretta M, Pugliese S, Valente D, Ciaffarafa S, Di Francia R. Evaluation of genotyping methods and the relative cost of pharmacogenomics. Eur Rev Med Pharmacol Sci. 2014;18(14):2084–2087.
   Web of Science ®Google Scholar
• Plöthner M, Ribbentrop D, Hartman J-P, Frank M. Cost-effectiveness of pharmacogenomic and pharmacogenetic test-guided personalized therapies: a systematic review of the approved active substances for personalized medicine in Germany. Adv Ther. 2016;33(9):1461–1480. doi:10.1007/s12325-016-0376-8
   PubMed Web of Science ®Google Scholar
• Plumpton CO, Roberts D, Pirmohamed M, Hughes DA. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. PharmacoEconomics. 2016;34(8):771–793. doi:10.1007/s40273-016-0397-9
   PubMed Web of Science ®Google Scholar
• Fragoulakis V, Bartsakoulia M, Díaz-Villamarín X, et al. Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention. Pharmacogenomics J. 2019;19(5):438–445. doi:10.1038/s41397-019-0069-1
   Web of Science ®Google Scholar
• Martin A, Downing J, Maden M, et al. An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review. Pharmacogenomics. 2017;18(16):1541–1550. doi:10.2217/pgs-2017-0076
   Web of Science ®Google Scholar
• Groessl EJ, Tally SR, Hillery N, Maciel A, Garces JA. Cost-effectiveness of a pharmacogenetic test to guide treatment for major depressive disorder. J Manag Care Spec Pharm. 2018;24(8):726–734.
   PubMed Web of Science ®Google Scholar
• Corponi F, Fabbri C, Serretti A. Pharmacogenetics and depression: a critical perspective. Psychiatry Investig. 2019;16(9):645–653. doi:10.30773/pi.2019.06.16
   Web of Science ®Google Scholar
• van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Jukić MM. Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going? Front Psychiatry. 2020;11:94. doi:10.3389/fpsyt.2020.00094
   Web of Science ®Google Scholar
• Li KX, Loshak H. Pharmacogenomic testing in depression: a review of clinical effectiveness, cost-effectiveness, and guidelines [Internet]. Pharmacogenomic testing in depression: a review of clinical effectiveness, cost-effectiveness, and guidelines. Can Agency Drugs Technol Health. 2020 [cited December 7, 2020]. Available from. http://www.ncbi.nlm.nih.gov/pubmed/33074624. Accessed July 28, 2021.
   Google Scholar
• Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder?: a systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry. 2017;78:720–729. doi10.4088/JCP.15r10583
   PubMed Web of Science ®Google Scholar
• Peterson K, Dieperink E, Ferguson L, Anderson J, Helfand M. Evidence brief: the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder [Internet]. VA Evidence-based Synthesis Program Evidence Briefs; 2011 [cited December 7, 2020]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27606389. Accessed July 28, 2021.
   Google Scholar
• Fabbri C, Kasper S, Zohar J, et al. Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. J Affect Disord. 2020;279:722–729. Elsevier BV.
   Web of Science ®Google Scholar
• Girardin FR, Poncet A, Perrier A, et al. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. Pharmacogenomics J. 2019;19(2):211–218. doi:10.1038/s41397-017-0004-2
   Web of Science ®Google Scholar
• Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17:395–402. doi10.1038/tpj.2017.21
   PubMed Web of Science ®Google Scholar
• Kim E, Levy R, Pikalov A. Personalized treatment with atypical antipsychotic medications. Adv Ther. 2007;24:721–740. doi:10.1007/BF02849966
   PubMed Web of Science ®Google Scholar
• Moore T, Hill A, Panguluri S. Pharmacogenomics in psychiatry: implications for practice. Recent Pat Biotechnol. 2014;8(2):152–159. doi:10.2174/1872208309666140904113615
   PubMedGoogle Scholar
• Carrascal-Laso L, Franco-Martín MÁ, García-Berrocal MB, et al. Application of a pharmacogenetics-based precision medicine model (5SPM) to psychotic patients that presented poor response to neuroleptic therapy. J Pers Med. 2020;10(4):1–16. doi:10.3390/jpm10040289
   Web of Science ®Google Scholar
• de Leon J, Susce MT, Murray-Carmichael E. The AmpliChipTM CYP450 genotyping test. Mol Diagn Ther. 2012;10(3):135–151. doi:10.1007/BF03256453
   Web of Science ®Google Scholar
• Gaedigk A, Whirl‐Carrillo M, Pratt VM, Miller NA, Klein TE. PharmVar and the landscape of pharmacogenetic resources. Clin Pharmacol Ther. 2020;107(1):43–46. doi:10.1002/cpt.1654
   Web of Science ®Google Scholar